Zoetis Inc. (ZTS) stock analysis

Healthcare · Drug Manufacturers - Specialty & Generic

From the 10-K filed 2026-02-12

Business type: Franchise

How it makes money

Companion animal products generate 70% of revenue, led by Simparica and Apoquel product lines contributing 16% and 12% of total revenue.

Zoetis earns revenue by commercializing pharmaceutical products, vaccines, parasiticides, anti-infectives, and diagnostics across companion animals (dogs, cats, horses) and livestock (cattle, swine, poultry, fish, sheep).

Companion animal products account for 70% of total revenue, driven by pet owner medical spending and extended pet lifespans. Its top-selling parasiticides (Simparica and Simparica Trio) and dermatology treatments (Apoquel and Apoquel Chewable) generate 16% and 12% of overall revenue, respectively.

Livestock products contribute 29% of revenue through anti-infectives, vaccines, and parasiticides sold to cattle, swine, and poultry producers to support food production.

What protects it: the moat

Brand loyalty from veterinarians persists after patent expiration, while regulatory data exclusivity protects marketing rights for key products.

Zoetis protects its earnings using patent exclusivity and regulatory data protection across its primary product categories. Unlike human healthcare, animal health benefits from high customer brand loyalty among veterinarians and pet owners that frequently persists even after patent expiration.

The business extends market exclusivity through continuous product lifecycle innovation—adding species claims, developing convenient chewable forms, and creating combination therapies like Simparica Trio.

What growth costs

Zoetis incurred $698 million in R&D in 2025 while expanding manufacturing capabilities across its existing production network.

To maintain and expand its earnings, Zoetis invests heavily in R&D, spending $698 million in 2025 across more than 300 research programs. R&D operations are co-located with manufacturing facilities globally to streamline production transfers.

Capital expenditure is directed toward expanding manufacturing capacity across its 21 internal manufacturing sites and coordinating over 90 third-party contract manufacturing organizations.

What could damage it

Post-patent generic competition can rapidly reduce core revenue, as demonstrated when Draxxin sales declined 66% in the U.S.

Zoetis faces earnings impairment when key original products lose patent protection and generic competitors launch lower-priced alternatives. Because top-selling products account for a significant share of earnings, generic substitution threatens long-term profitability.

When its cattle and swine antibiotic Draxxin encountered generic entry starting in 2021, price pressure and market share loss drove a 66% sales decline in the U.S. A similar wave of generic entry against core companion animal lines could permanently impair cash generation.

About Zoetis Inc.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

More on ZTS

Other companies in Drug Manufacturers - Specialty & Generic